HIV-CORE 003
Status:Completed
Phase:I/II
Principal Investigator(s):Julian D Gillmore, MBBS
Objective:This is a clinical proof-of-concept (PoC) study of DNA vaccination after SAP depletion. The investigators will measure the immune responses to DNA vaccination against HIV-1 in healthy adult male volunteers, comparing a group in whom SAP has been completely depleted at the time of DNA vaccination and a control group vaccinated without SAP depletion.
Note: The recruitment status of this study is unknown and has not been verified.
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Official Code:
NCT02425241
Trial Sponsors:
GlaxoSmithKline, London, Medical Research Council, University College, University of Oxford
Start Date
End Date
October 24, 2013
December 24, 2015
Enrollment:40
Age range:
18 Years ↔
50 Years
Population:Cisgender Men